Cover Image

美國的非侵入性產前遺傳檢測 (NIPT) 市場預測

US Non-Invasive Prenatal Testing Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 297684
出版日期 內容資訊 英文 70 Pages
Back to Top
美國的非侵入性產前遺傳檢測 (NIPT) 市場預測 US Non-Invasive Prenatal Testing Market Outlook 2020
出版日期: 2015年05月01日 內容資訊: 英文 70 Pages

美國的生產女性的平均年齡,年年上升。初次生產是35歲,或是40歲也不新奇。可是,隨著母親的年齡上,兒童染色體異常發病的風險會增加。美國的非侵入性產前遺傳檢測 (NIPT) 市場,預計今後數年以2位數成長。


第1章 分析師的見解

第2章 調查手法

第3章 美國的NIPT市場上可利用的檢驗

  • MaterniT21
  • Verifi
  • Panorama
  • Harmony

第4章 市場上目前技術

第5章 胎兒的唐氏症 (DS) 風險與母親年齡之間的關聯

第6章 人口統計預測

  • 人口統計
  • 出生數:現在、未來
  • 疾病的人口統計

第7章 美國的NIPT:潛在市場

第8章 美國的NIPT市場預測

  • 市場規模與預測
  • 企業的市場佔有率

第9章 法規的考察

第10章 美國的NIPT市場償付方案

第11章 競爭評估

  • 產業概要、優勢和弱點、最近的趨勢
    • Ariosa Diagnostics
    • Sequenom
    • Verinata
    • Natera




The non-invasive prenatal testing market in US, which is extremely lucrative and a growing segment of the diagnostics industry, is driven by companies developing and offering these tests. The average age of women giving birth in United States has increased over the years. It's no longer unusual for women to have a first child at age 35 or even 40. This trend has been attributed to numerous factors such as recession and associated affordability issues, and women being more focused on their careers than before. However, increased age of the mother also increases the risk of her child developing chromosomal abnormalities. This risk has thus paved the way for NIPT tests which have emerged as the next big thing in the field of prenatal diagnostics.

According to our report "US Non-Invasive Prenatal Testing Market Outlook 2020", the rise in high risk births has been contributing to the growth of the NIPT market which is anticipated to witness an impressive double digit growth in the next few years. Our report provides a detailed insight into the current scenario and future outlook of the US NIPT market. It has been inferred that most of the total market remains untapped. Contribution of every NIPT player has also been provided in terms of current and future market shares.

The demographic scenario of United States has been discussed with focus on the current and future number of births, with the demographics segregated by age and state. Although the market has witnessed stupendous growth and new tests have gained acceptance rapidly, much of it still remains untapped due to various reasons. This has been discussed in the section dedicated to the potential market for 2014 and 2020.

A thorough analysis too has been done illustrating the views of regulatory authorities, players and consumers towards regulatory stringency and the direction of regulations in the future have also been covered.

Research and innovation in this field is at its peak, and market players are conducting validation studies to check the level of specificity and sensitivity while comparing clinical tests. Already several clinical trials in the pipeline upon completion may impact the overall market in a significant manner.

The US NIPT sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These players have been profiled with their strengths and weaknesses and latest developments in the field of NIPT. The report provides a prudent analysis of the current and future size of the market weighing the possible pessimistic and optimistic scenarios and is a must buy for players planning to enter the prenatal segment.

Table of Contents

1. Analyst View

2. Research Methodology

3. Tests Available in the US NIPT Market

  • 3.1 MaterniT21
  • 3.2 Verifi
  • 3.3 Panorama
  • 3.4 Harmony

4. Current Technologies in the Market

5. Association of Down's syndrome Risk to Fetus with Mother's Age

6. Demographics Outlook

  • 6.1 Population Demographics
  • 6.2 Number of Births: Current and Future
    • 6.2.1 By Age Group
    • 6.2.2 By State
  • 6.3 Disease Demographics

7. US NIPT - Potential Market (2014 & 2020)

8. US NIPT Market Projections to 2020

  • 8.1 Market Size and Forecast
  • 8.2 Market Share of Players

9. Regulatory Insight

  • 9.1 Current Regulatory Scenario
  • 9.2 Regulatory Authority Perspective
  • 9.3 Diagnostic Test Provider Perspective
  • 9.4 ACOG Opinion
  • 9.5 Consumers' Perspective
  • 9.6 Analyst Inputs

10. Reimbursement Scenario for US NIPT Market

11. Competitive Assessment

  • 11.1 Ariosa Diagnostics
    • 11.1.1 Business Overview
    • 11.1.2 Strengths and Weaknesses
    • 11.1.3 Recent Developments
  • 11.2 Sequenom
    • 11.2.1 Business Overview
    • 11.2.2 Strengths and Weaknesses
    • 11.2.3 Recent Developments
  • 11.3 Verinata
    • 11.3.1 Business Overview
    • 11.3.2 Strengths and Weaknesses
    • 11.3.3 Recent Developments
  • 11.4 Natera
    • 11.4.1 Business Overview
    • 11.4.2 Strengths and Weaknesses
    • 11.4.3 Recent Developments

List of Figures:

  • Figure 3-1: Verifi Test Validation Results
  • Figure 3-2: Panorma Test Validation Results
  • Figure 3-3: Harmony Test Validation Results
  • Figure 5-1: Risk of Down's syndrome with Rise in Maternal Age
  • Figure 6-1: Population (Million), 2014-2020
  • Figure 6-2: Male-Female Ratio (%), 2014
  • Figure 6-3: Number of Births (Million), 2010-2014
  • Figure 6-4: Number of Births (Million), 2014-2020
  • Figure 7-1: Number of Births by Mother's Risk of Down's syndrome (%), 2014
  • Figure 7-2: High Risk NIPT Potential Market (Million US$), 2014 & 2020
  • Figure 7-3: Medium Risk NIPT Potential Market (Million US$), 2014 & 2020
  • Figure 8-1: Non-Invasive Prenatal Diagnostics Market (Million US$), 2014-2020
  • Figure 8-2: NIPT Market Penetration in High Risk Category (2014)
  • Figure 8-3: Share of Players in Number of NIPT Tests Performed (2014)
  • Figure 8-4: Share of Players in NIPT Market (2014)
  • Figure 8-5: Forecast for Share of Players in Number of NIPT Tests Performed (2020)
  • Figure 8-6: Forecast for Share of Players in NIPT Market (2020)
  • Figure 9-1: Laboratorians' Attitudes towards FDAs Regulations on Lab Developed Tests (LDT)

List of Tables:

  • Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
  • Table 3-2: MaterniT21 PLUS Test Validation Results
  • Table 4-1: Common Commercial Kits and Protocols for Isolation of ccff DNA from Maternal Plasma
  • Table 6-1: Births by Women Age-Group (%), 2014-2020
  • Table 6-2: Top Ten States by Number of Births (2012 & 2013)
  • Table 6-3: Prevalence of Chromosomal Abnormalities
  • Table 9-1: Inter-comparison of CLIA and FDA Regulatory Pathway
  • Table 10-1: Comparative Analysis of Tests Available in US NIPT Market
Back to Top